Selective cholesterol absorption inhibition as a new prospect in treatment of hypercholesterolemia;Inhibición selectiva de la absorción de colesterol: Una nueva perspectiva en el tratamiento de la hipercolesterolemia

Medicina Clinica

Volumn 125, Issue 1, 2005, Pages 16-23

  Lima, Joan ^a   Fonollosa, Vicent ^a   Chacón, Pilar ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cholesterol absorption inhibitors; Ezetimibe; Treatment of hypercholesterolemia

Indexed keywords

2 AZETIDINONE DERIVATIVE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIVER ENZYME; PLACEBO;

CHOLESTEROL BLOOD LEVEL; DRUG ABSORPTION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; INTESTINE ABSORPTION; MIGRAINE; MONOTHERAPY; MYOPATHY; PAIN; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 21744441933     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076400     Document Type: Review

References (89)

1. Boix R, Medrano MJ, Almazán J. Actualización de la mortalidad por enfermedades cardiovasculares arterioscleróticas: enfermedad cerebrovascular y enfermedad isquémica del corazón. Boletín Epidemiológico Semanal. 2000;8:77-84.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholestemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279:1615-22.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in. 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
5. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9.
7. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl J Med. 1998;338:1349-57.
8. Serruys PW, Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA. 2002;287:3215-22.
9. ASCOT investigators group. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentration in ASCOT-LLA: a multicentre randomized controlled trial. Lancet. 2003;361:1149-58.
10. Frolkis JP, Pearce GP, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002;113:625-9.
11. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160: 459-67.
12. Gómez-Belda A, Rodilla E, Albert A, García L, González C, Pascual JM. Uso clínico de las estatinas y objetivos terapéuticos en relación con el riesgo cardiovascular. Med Clin (Barc). 2003;121:527-31.
13. Grundy SM. Alternative approaches to cholesterol-lowering therapy. Am J Cardiol. 2002;90:1135-8.
14. Ros E. Digestión y absorción de las grasas. Posibilidades de modulación dietética y farmacológica. Med Clin (Barc). 1999;113:337-48.
15. Wilson MD, Rudel LL. Review of cholesterol absorption with emphasis on dietary and biliary cholesterol. J Lipid Res. 1994;35:943-55.
16. Kesäniemi YA, Miettinen TA. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest. 1987;17:391-5.
17. Bosner SM, Lange LG, Stenson WF, Oslund RE. Percent cholesterol absorption in normal women and men quantified with dual stable isotropic tracers and negative ion mass spectrometry. J Lipid Res. 1999;40:302-8.
18. Nissinen M, Gylling H, Vuoristo M, Miettinen TA. Micellar distribution of cholesterol and phytosterols after duodenal plant stanol ester infusion. Am J Physiol. 2002;282:1009G-15G.
19. Beil FU, Grundy SM. Studies on plasma lipoproteins during absorption of exogenous lecithin in man. J Lipid Res. 1980;21:526-36.
20. Vahouny GV, Tombes R, Cassidy MM, Kritchesvsky D, Gallo LL. Dietary fibers: V. Binding of bile salts, phospholipids and cholesterol from mixed micelles by bile acid sequestrants and dietary fibers. Lipids. 1980;15:1012-8.
21. Ninomiya R, Matsuoka K, Moroi Y. Micelle formation of sodium chenodeoxycolate and solubilization into the micelles: comparison with other unconjugated bile salts. Biochim Biophys Acta. 2003;1634:116-25.
22. Mittendorfer B, Oslund RE Jr, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res. 2001;9:599-604.
23. Grundy S. Absorption and metabolism of dietary cholesterol. Ann Rev Nutr. 1983;3:71-96.
24. Dawson PA, Rudel LL. Intestinal cholesterol absorption. Curr Opin Lipidol. 1999;10:315-20.
25. Graf GA, Li WP, Gerard RD, Gelissen I, White A, Cohen JC, et al. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest. 2002;110:659-69.
26. Yu L, Hammer RE, Li-Hawkins J, von Bergmann K, Lutjohann D, Cohen JC, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA. 2002; 99:16237-42.
27. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest. 2002;110:671-80,
28. Berge KE, Tian H, Graf GA, Yu L, Grihin NV, Schultz J, et al. Accumulation of dietary cholesterol in sistosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290:1771-5.
29. Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2 encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet. 2001; 69:278-90.
30. Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest. 1974; 53:1033-43.
31. Sehayek E, Duncan EM, Lutjohann D, von Bergmann K, Ono JG, Batta AK, et al. Loci on chromosomes 14 and 2, distinct from ABCG5/ABCG8, regulate plasma plant sterols levels in a C57BL/6J × CASA/Rk intercross. Proc Nat Acad Sci USA. 2002;99:16215-9.
32. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 2002;277:18793-800.
33. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943-8.
34. Lutjohann D, Björhem I, Beil UF, Von Bergmann K. Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. J Lipid Res. 1995;36:1763-73.
35. Turley SD, Dietschy JM. Sterol absorption by the small intestine. Curr Opin Lipidol. 2003;14:233-40.
36. Kramer W, Girbig F, Corsiero D, Burger K, Fahrenholz F, Jung C, et al. Intestinal cholesterol absorption: identification of different binding proteins for cholesterol and cholesterol absorption inhibitors in the enterocyte brush border membrane. Biochim Biophys Acta. 2003;1633:13-26.
37. Gordon DA, Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B assembly. Biochim Biophys Acta. 2000;1486:72-83.
38. Chang TY, Chang CCY, Lin S, Yu C, Li BL, Miyazaki A. Roles of acyl-co-enzyme A: cholesterol acyltransferase-1 and -2. Curr Opin Lipidol. 2001; 12:289-96,
39. Insull W Jr, Koren M, Davignon J, Sprecher D, Schrott H, Keilson LM, et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 2001;157:137-44.
40. Raal FJ, Marais AD, Klepack E, Lovalvo J, Mclain R, Heinonen T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis. 2003;171:273-9.
41. Sudhop T, Von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Drugs. 2002;62:2333-47.
42. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-59.
43. Ros E. El colesterol de la dieta y su escasa influencia sobre la colesterolemia y el riesgo cardiovascular. Clin Invest Arterioscler. 2000;12 Supl 2:20-6.
44. Sehayek E. Genetic regulation of cholesterol absorption and plasma plant sterols levels: commonalities and differences. J Lipid Res. 2003; 44:2030-8.
45. Von Bergmann K, Lutjohann D, Lindenthal B, Steinmetz A. Efficiency of intestinal cholesterol absorption in humans is not related to ApoE phenotipe. J Lipid Res. 2003;44:193-7.
46. Thompson GR, O'Neill, Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J. 2002;23:200-6.
47. Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest. 2003;33:976-82.
48. Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol predicts recurrent coronary events in a subgroup of the Scandinavian Simvastatin Survival Study (4S). BMJ. 1998;316:1127-30.
49. Miettinen TA, Gylling H. Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S sub-group. Atherosclerosis. 2003;168:343-9.
50. Van Heek M, Parley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodens in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001; 134:409-17.
51. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drugs Metab Dispos. 2002;30:430-7.
52. Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther. 2001;23:871-85.
53. Darkes MJM, Poole RM, Goa KL. Ezetimibe. Am J Cardiovasc Drugs. 2003;3:67-76.
54. Simard C, Turgeon J. The pharmacokinetics of ezetimibe. Can J Clin Pharmacol. 2003;10 Suppl A:13-20.
55. Van Heek M, Parley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129:1748-54.
56. Repa JJ, Dietschy JM, Turley SD. Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte. J Lipid Res. 2002;43:1864-74.
57. Salen G, Von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004;109:966-71.
58. Kramer W, Glombik H, Petry S, Heuer H, Schäfer HL, Wendler W, et al. Identification of binding proteins for cholesterol absorption inhibitors as components of the intestinal cholesterol transporter. FEBS Lett. 2000; 487:293-7.
59. Altmann SW, Davis HR, Zhu L, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201-4.
60. Davis HR, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2001;21:2032-8.
61. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, Le Beaut AP, Suresh R, et al. Efficacy and safety of a new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-7.
62. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729-41.
63. Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-91.
64. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, Le Beaut AP, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-34.
65. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. Circulation. 2003;107:2409-15.
66. Melani L, Mills R, Hassman D, Lipetz R, Lipka LJ, Le Beaut AP, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003;24:717-28.
67. Kerzner B, Cobelli J, Sharp S, Lipka LJ, Melani L, Le Beaut AP, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003;91:418-24.
68. Stein E, Stender S, Mata P, Ponsonnet D, Melani L, Lipka LJ, et al. Coadmnistration of ezetimibe plus atorvastatin [abstract]. Atheroscler. 2002;3Suppl:211-2.
69. Vermaak W, Pinto X, Ponsonnet D, Sager P, Lipka LJ, Suresh R, et al. Heterozygous familial hypercholesterolemia: coadmnistration of ezetimibe plus atorvastatin [abstract]. Atheroscler. 2002;3 Suppl:230-1.
70. Thompson GR. LDL apheresis. Atherosclerosis. 2003;167:1-13.
71. Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-75.
72. Van Heek M, Davis H. Pharmacology of ezetimibe [abstract]. Eur Heart J. 2002;4Suppl J:17-20.
73. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, et al. Pharmacodynamic interaction between the new selective cholesterol absortion inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002;54:309-19.
74. Zhu Y, Statkevich P, Kosoglou T, Maxwell SE, Anderson L, Patrick JE, et al. Lack of a pharmacokinetics interaction between ezetimibe and atorvastatin [abstract]. Clin Pharmacol Ther. 2001;69:68P.
75. Reyderman L, Kosoglou T, Statkevich P, Anderson L, Boutros T, Batra V, et al. No pharmacokinetic drug interaction between ezetimibe and lovastatin [abstract]. Clin Pharmacol Ther. 2001;69:66P.
76. Kosoglou T, Meyer I, Musiol B, Anderson L, Reyderman L, Statkevich P, et al. Pharmacodynamic interaction between fluvastatin and ezetimibe has favourable clinical implications [abstract]. Atheroscler. 2001;2 Suppl:89.
77. Kosoglou T, Guillaume M, Sun S, Pember LJC, Reyderman L, Statkevich P, et al. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe [abstract]. Atheroscler. 2001;2 Suppl:38.
78. Cada DJ, Levien T, Baker DE. Ezetimibe. Hosp Pharm. 2003;38:357-66.
79. Ballantyne C. Ezetimibe: efficacy and safety in clinical trials [abstract]. Eur Heart J. 2002;4 Suppl J:5-15.
80. Knopp RH, Dujovne CA, LeBeaut AP, Lipka LJ, Suresh R, Vetri EP. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003;57:363-8.
81. Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA. 1987;257:33-8.
82. Hunninghake D, Insull W, Toht P, Davisdon D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158:407-16.
83. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110:352-60.
84. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-98.
85. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-62.
86. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol. 2000;86;46-52.
87. McKenney J. Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. Am J Cardiol. 2002;90Suppl:8K-20K.
88. Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidants vitamins, or the combination for the prevention of coronary disease. N Eng J Med. 2001;345:1583-92.
89. Brown WV. Cholesterol absorption inhibitors: defining new options in lipid management. Clin Cardiol. 2003;26:259-64.